With insomnia, the figures are staggering: nearly one-third of Americans experience some level of sleep disruption, and for ...

Suvorexant belongs to a new class of sleep medications called dual orexin receptor antagonists. Orexin is a molecule that promotes wakefulness; suvorexant blocks it, promoting deeper sleep.

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

The use of AI in sleep medicine continues to evolve, said D’Ambrosio. She cited a recent review in the Journal of Clinical ...

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy ...